Subscribe to Newsletter

Venkata Indurthi

Chief Scientific Officer of Aldevron, a Danaher Life Sciences company that works with CRISPR innovators from early research through clinical use, providing custom nucleases, next-generation plasmid vectors, RNP complexing and analytic services, and more. He has been a member of the Aldevron team since he received his doctorate in pharmaceutical sciences from North Dakota State University, Fargo, ND, in 2016.

Content by Venkata Indurthi:

 Manufacture Advanced Medicine

Next Generation CRISPR

| Venkata Indurthi | 3 min read

The pipeline of early-stage CRISPR therapeutics is huge, but advancing these innovations will require a multifaceted strategy.
Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

October Issue of The Medicine Maker